(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Soligenix begins confirmatory phase 3 trial of HyBryte for treatment of cutaneous T-cell lymphoma: Princeton, New Jersey Wednesday, December 18, 2024, 14:00 Hrs [IST] Soligenix, I ...
FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused ...
The Phase I expansion trial saw a 25.9% overall response rate (ORR) for endometrial cancer and 37.5% in platinum-resistant ...
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On Soligenix, Inc ...
Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate, trumpeting a 100% complete response rate but ...
Repare Therapeutics (RPTX) reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of ...
TopSpeed on MSN1d
Honda Continues Investing In Its Hydrogen AmbitionsHonda has multiple goals with the expansion of its fuel cell business. One is to capture more of the market share of ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback